Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 3/2020

01-06-2020 | Herpes Virus | Case Report

Multiple esophageal ulcers due to tofacitinib 10 mg twice daily for ulcerative colitis

Authors: Keiichi Tominaga, Mimari Kanazawa, Kazuhiro Takenaka, Takanao Tanaka, Takeshi Sugaya, Koh Fukushi, Yuka Takagi, Kazunori Nagashima, Keiichiro Abe, Naoya Izawa, Kohei Tsuchida, Makoto Iijima, Kenichi Goda, Hidetsugu Yamagishi, Atsushi Irisawa

Published in: Clinical Journal of Gastroenterology | Issue 3/2020

Login to get access

Abstract

A 26-year-old man was admitted to our institution for ulcerative colitis treatment. He used mesalamine, steroid, immunomodulators, and anti-TNFα anti-body, but it was difficult to maintain remission. We started induction therapy with tofacitinib (TOF) 10 mg twice daily. He maintained clinical remission but had chest pain 44 days after the start of TOF. Esophagogastroduodenoscopy showed multiple ulcers from middle to lower esophagus. Although rare, TOF induced esophageal ulcers were considered based on his clinical course and endoscopic findings.
Literature
1.
go back to reference Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.CrossRef Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.CrossRef
2.
go back to reference Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36.CrossRef Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36.CrossRef
3.
go back to reference Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258–65.CrossRef Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258–65.CrossRef
4.
go back to reference Motoya S, Watanabe M, Kim HJ, et al. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018;16:233–45.CrossRef Motoya S, Watanabe M, Kim HJ, et al. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018;16:233–45.CrossRef
5.
go back to reference Jung KH, Choi J, Gong EJ, et al. Can endoscopists differentiate cytomegalovirus esophagitis from herpes simplex virus esophagitis based on gross endoscopic findings? Medicine (Baltimore). 2019;98:e15845.CrossRef Jung KH, Choi J, Gong EJ, et al. Can endoscopists differentiate cytomegalovirus esophagitis from herpes simplex virus esophagitis based on gross endoscopic findings? Medicine (Baltimore). 2019;98:e15845.CrossRef
6.
go back to reference Werneck-Silva AL, Prado IB. Role of upper endoscopy in diagnosing opportunistic infections in human immunodeficiency virus-infected patients. World J Gastroenterol. 2009;15:1050–6.CrossRef Werneck-Silva AL, Prado IB. Role of upper endoscopy in diagnosing opportunistic infections in human immunodeficiency virus-infected patients. World J Gastroenterol. 2009;15:1050–6.CrossRef
7.
go back to reference Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24:2173–82.CrossRef Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24:2173–82.CrossRef
Metadata
Title
Multiple esophageal ulcers due to tofacitinib 10 mg twice daily for ulcerative colitis
Authors
Keiichi Tominaga
Mimari Kanazawa
Kazuhiro Takenaka
Takanao Tanaka
Takeshi Sugaya
Koh Fukushi
Yuka Takagi
Kazunori Nagashima
Keiichiro Abe
Naoya Izawa
Kohei Tsuchida
Makoto Iijima
Kenichi Goda
Hidetsugu Yamagishi
Atsushi Irisawa
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 3/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-019-01061-y

Other articles of this Issue 3/2020

Clinical Journal of Gastroenterology 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.